How to Map a Patient Journey Without Inventing a Linear Funnel
A method for turning patient research into a branching journey map with an assumption ledger and testable media implications.
The short answer
Patient journey maps often look like tidy funnels: awareness, symptoms, diagnosis, treatment, adherence. Real journeys branch, loop, and stall. A person may be diagnosed years after symptoms start, try three therapies, stop treatment, and restart. A journey map that ignores this leads to media plans that target the wrong moments.
The goal is not a prettier diagram. It is a map that produces testable media decisions.
Start with barriers, not stages
Instead of asking "what stage is the patient in," ask "what stops the patient from moving forward." Barriers are more actionable for media. Common barrier types include:
- Recognition: symptoms are dismissed or attributed to something else.
- Access: difficulty finding or reaching an appropriate clinician.
- Conversation: reluctance to raise the topic with a doctor.
- Treatment hesitancy: concerns about side effects, cost, or administration.
- Persistence: difficulty staying on therapy.
Media can plausibly address some barriers, such as recognition and conversation. It has limited effect on others, like insurance coverage. Be honest about which is which.
Build a branching map
Draw the journey as a set of states connected by possible transitions, including backward moves. For each transition, note:
- What typically triggers it.
- What barrier slows it.
- Whether media can plausibly help.
- What information need exists at that point.
A branching map shows, for example, that many people cycle between "diagnosed, untreated" and "treated, then discontinued." That loop may be a larger opportunity than first-time diagnosis.
Keep an assumption ledger
Every journey map rests on assumptions. Write them down with their source and confidence.
| Assumption | Source | Confidence | How to test |
|---|---|---|---|
| Most patients search symptoms before seeing a doctor | Published survey, 2023 | Medium | Search trend and site entry analysis |
| Caregivers drive most initial appointments | Brand qualitative research | Low | Caregiver audience test cell |
| Side-effect concerns drive most discontinuation | Published literature | Medium | Not testable by media alone |
This ledger keeps the team honest. When a media plan leans heavily on a low-confidence assumption, the ledger shows it.
Turn the map into media implications
For each transition where media can help, write one media implication and one way to check it. For example: "If recognition is the main barrier, symptom-focused contextual placements should drive more site entries to symptom content than brand content. Check with site analytics by entry page."
Use reputable sources
Use published disease research, patient advocacy group materials, and brand-owned research. FDA patient-facing materials, including resources on rare diseases, can help frame language. Avoid building a journey from a single survey or from media partner data alone.
Common mistakes
One journey for all patients. Different subgroups have different paths. Map at least two if the brand serves distinct populations.
Ignoring caregivers. In some conditions, caregivers shape every step. See caregiver audience strategy.
Stopping at the prescription. Adherence and persistence are often where brands lose the most patients. Consider patient support handoffs.
Practical takeaway
Replace the linear funnel slide with two artifacts: a branching state map with barriers noted on each transition, and an assumption ledger. Every media tactic in the plan should point to a transition on the map.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.